title: Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital.
abstract: OBJECTIVE
  To investigate whether high-dose therapy with hematopoietic stem-cell rescue (HSCR) will improve survival for patients with relapsed Wilms' tumor.
  
  
  METHODS
  Thirteen children with relapsed Wilms' tumor were treated with one or two cycles of high-dose chemotherapy (HDT) followed by autologous HSCR. Twelve of 13 patients received reinduction chemotherapy before HDT and HSCR. The median age at diagnosis was 4.8 years, and the median time to relapse was 12 months. The histology was favorable in 12 of 13 patients. The ablative regimens included: (1) thiotepa (TT)/cyclophosphamide (CTX)/carboplatin (CP; n = 2); (2) TT/CTX (n = 5); (3) TT/etoposide (ETP; n = 1); and (4) CP/ETP/CTX (n = 1). Four patients received two cycles of HDT and HSCR. Cycle 1 consisted of CP/ETP/CTX, and melphalan/CTX were used in cycle 2.
  
  
  RESULTS
  Seven of 13 patients are alive without evidence of disease, with a median follow-up of 30 months. The 4-year estimated event-free survival (EFS) rate is 60% (95% CI, 0.40 to 6.88), and the overall survival (OS) at 4 years is 73% (95% CI, 0.40 to 6.86). There was no transplant-related mortality. All patients engrafted to an absolute neutrophil count 500/microL at a median of 13 days (range, 8 to 62 days) and had an unsustained platelet count > 20.0 micro at a median of 16 days (range, 10 to 202 days).
  
  
  CONCLUSIONS
  Our results suggest that HDT with HSCR is an effective treatment for patients with Wilms' tumor who experience relapse.
authors.affiliation: Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL 60614, USA.
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Campbell
authors.forename: Susan L
authors.initials: SL
authors.lastname: Cohn
authors.forename: Marleta
authors.initials: M
authors.lastname: Reynolds
authors.forename: Roopa
authors.initials: R
authors.lastname: Seshadri
authors.forename: Elaine
authors.initials: E
authors.lastname: Morgan
authors.forename: Grant
authors.initials: G
authors.lastname: Geissler
authors.forename: Alfred
authors.initials: A
authors.lastname: Rademaker
authors.forename: Maryann
authors.initials: M
authors.lastname: Marymount
authors.forename: John
authors.initials: J
authors.lastname: Kalapurakal
authors.forename: Paul R
authors.initials: PR
authors.lastname: Haut
authors.forename: Reggie
authors.initials: R
authors.lastname: Duerst
authors.forename: Morris
authors.initials: M
authors.lastname: Kletzel
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007223:Infant; D007680:Kidney Neoplasms / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D016019:Survival Analysis; D013852:Thiotepa / Q000008:administration & dosage; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D009396:Wilms Tumor / Q000628:therapy*
chemical_list: D005047:Etoposide; D003520:Cyclophosphamide; D013852:Thiotepa; D016190:Carboplatin; D008558:Melphalan